Abstract
Systemic delivery of leuprolide acetate, a luteinizing hormone releasing hormone (LHRH) agonist, was compared after inhalation (i.h.) and intranasal (i.n.) administration. The i.n. bioavailability in rats was significantly increased by α-cyclodextrin (CD), EDTA, and solution volume. Intraanimal variability was 30–60%, and absorption ranged from 8 to 46% compared to i.v. controls. Studies in healthy human males were conducted with leuprolide acetate i.n. by spray, or inhalation aerosol (i.h.), and subcutaneous (s.c.) and intravenous (i.v.) injection. The s.c. injection was 94% bioavailable compared with i.v. The i.n. bioavailability averaged 2.4%, with significant subject-to-subject variability. Plasma peak concentrations (C max) with 1- and 3-mg dosages ranged between 0.24–1.6 and 0.10–11.0 ng/ml, respectively. The low human bioavailability may be due to physical loss of drug down the oral cavity and differences between human and rat nasal mucosa. Inhalation delivery gave a slightly lower intersubject variability. Mean C max with a 1-mg dose of solution aerosol was 0.97 ng/ml, compared with 4.4 and 11.4 ng/ml for suspension aerosols given at 1- and 2-mg bolus dosages, respectively. The mean bioavailability of the suspension aerosols (28% relative to s.c. administration) was fourfold greater than that of the solution aerosol (6.6%), suggesting that LHRH analogues may be delivered systemically via the lung as aerosol dispersions.
Similar content being viewed by others
REFERENCES
A. V. Schally, A. J. Kastin, and A. Arimura. Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: Structure, physiology, and clinical studies. Fertil. Steril. 22:703–721 (1971).
P. E. Belchetz, P. M. Plant, Y. Nakai, E. J. Keogh, and E. Knobil. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 202(4368):631–633 (1978).
The Leuprolide Study Group, M. M. Garnick, and thirty other participants. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N. Engl. J. Med. 311:1281–1286 (1984).
D. R. Meldrum, R. J. Chang, J. Lu, W. Vale, J. Rivier, and H. L. Judd. Medical oophorectomy using a long-acting GNRH agonist—A possible new approach to the treatment of endometriosis. J. Clin. Endocrinol. Metab. 54(5): 1081–1083 (1982).
A. Lemay, R. Maleux, N. Faure, C. Jean, and A. T. A. Fazekas. Efficacy and safety of LH-RH agonist treatment in 10 patients with endometriosis. J. Steroid Biochem. 20(N6B):1379 (1984).
M. Fujimoto, T. Fukuda, S. Shinagawa, S. Kobayashi, I. Yamazaki, R. Nakayama, J. H. Seely, W. F. White, and R. H. Rippel. Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) substituted in position 6 and 10. Biochem. Biophys. Res. Commun. 60(l):406–413 (1974).
R. H. Rippel, E. S. Johnson, W. F. White, M. Jugino, T. Fukuda, and S. Kobayashi. Ovulation and gonadotropin releasing activity of [D-Leu6,desGlyNH2 10,Pro-ethylaminde9]GnRH. Proc. Soc. Exp. Biol. Med. 148(4):1193–1197 (1975).
M. J. Kartenand J. E. Rivier. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: Rationale and perspective. Endocr Rev. 7(l):44–66 (1986).
I. Yamazaki and H. Okada. A radioimmunoassay for a highly active luteinizing hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin. Endocrinol. Jpn. 27(5):593–605 (1980).
A. Adjei, R. Doyle, M. Pratt, R. Finley, and E. Johnson. Bioavailability of leuprolide following intratracheal administration to beagle dogs. Int. J. Pharm. 61:135–144 (1990).
J. W. Sutherland and G. N. Menon. HPLC of leuprolide acetate in injectable solutions. J. Liq. Chromatogr. 10(10):2281–2289 (1987).
J. C. Marshall and W. D. Odell. Preparation of biologically active [125I]LH-RH suitable for membrane binding studies. Proc. Soc. Exp. Biol. Med. 149(2):351–355 (1975).
T. F. Hatch and P. Gross. Pulmonary Deposition and Retention of Inhaled Aerosols. American Industrial Hygiene Association and U.S. Atomic Energy Commission. Academic Press, New York, 1964, pp. 27–35.
A. Adjei, E. Johnson, R. Doyle, and K. Sims. Formulation of a nonapeptide: In-vitro and in-vivo studies. J. Pharm. Sci. 76(11):PS47 (1987).
P. R. Byron, R. N. Dalby, and A. J. Hickey. Optimized inhalation aerosols. I. The effects of spherical baffle and position upon the output of several pressurized nonaqueous suspension formulations. Pharm. Res. 3(6):225–229 (1989).
A. Adjei and J. Garren. Pulmonary delivery of peptide drugs: Effect of particle size on bioavailability of leuprolide acetate in healthy human male volunteers. Pharm. Res. 7:565–569 (1990).
H. Okada, I. Yamazaki, Y. Ogawa, S. Hirai, T. Yashiki, and H. Mima. Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats. I. Absorption by various routes and absorption enhancement. J. Pharm. Sci. 71(12):1367–1371 (1982).
R. L. Chan, M. R. Henzl, M. E. LePage, J. LaFargue, C. A. Nerenberg, S. Anik, and M. D. Chaplin. Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. Clin. Pharmacol. Ther. 44(3):275–282 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Adjei, A., Sundberg, D., Miller, J. et al. Bioavailability of Leuprolide Acetate Following Nasal and Inhalation Delivery to Rats and Healthy Humans. Pharm Res 9, 244–249 (1992). https://doi.org/10.1023/A:1018997625726
Issue Date:
DOI: https://doi.org/10.1023/A:1018997625726